知镜 Cognispect · 医学文献与研究工作台

Breast Cancer and Diabetes Mellitus: Epidemiology, Pathophysiology, and Clinical Outcomes.

Saeed H, Habib R, Arnold E, Ahmed S, Shahid RK.
American journal of medicine open · 2026-09-08 · PMID 42997824

文献摘要

Breast cancer and diabetes mellitus frequently coexist and share metabolic risk factors, with important implications for cancer risk, treatment, and survivorship. This review synthesizes epidemiologic, mechanistic, and clinical evidence, focusing on type 2 diabetes mellitus (T2DM), the subtype most consistently associated with breast cancer. Meta-analyses indicate that women with T2DM have a 20%-27% higher breast cancer risk than women without diabetes, particularly after menopause (RR 1.20, 95% CI 1.12-1.28; SRR 1.27, 95% CI 1.16-1.39). Potential mechanisms include hyperinsulinemia, insulin-like growth factor-1 signaling, inflammation, obesity-related metabolic dysfunction, and altered sex hormone metabolism. Among patients with breast cancer, diabetes is associated with more advanced disease at diagnosis, increased treatment-related toxicity, and infectious complications. Meta-analyses also demonstrate higher all-cause mortality among patients with diabetes (HR 1.49, 95% CI 1.35-1.65; adjusted HR 1.51, 95% CI 1.34-1.70). Conversely, breast cancer survivors face a modestly elevated risk of developing T2DM, particularly following endocrine therapy or chemotherapy. These bidirectional associations support integrating metabolic assessment and diabetes management into oncology care. Future research should prioritize prospective subtype-specific studies, standardized glucose monitoring during systemic therapy, trials of integrated care, and evaluation of newer antidiabetic agents. These priorities may clarify causality and guide evidence-based interventions across the cancer care continuum.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。